Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Endothelial cell glycogen synthase kinase 3β promotes lipotoxic endotheliopathy and liver inflammation in MASH
Akitoshi Sano, Qianqian Guo, Khaled Warasnhe, Chady Meroueh, Nantawat Satthawiwat, Asma Hamdi, Ghefar Hmaydoosh, Xin Dai, Usman Yaqoob, Kevin D. Pavelko, Charlene Miciano, Tatiana Kisseleva, Zeba Firdaus, Patrick P. Starlinger, David Pereyra, Enis Kostallari, Petra Hirsova, Davide Povero, Samar H. Ibrahim
Akitoshi Sano, Qianqian Guo, Khaled Warasnhe, Chady Meroueh, Nantawat Satthawiwat, Asma Hamdi, Ghefar Hmaydoosh, Xin Dai, Usman Yaqoob, Kevin D. Pavelko, Charlene Miciano, Tatiana Kisseleva, Zeba Firdaus, Patrick P. Starlinger, David Pereyra, Enis Kostallari, Petra Hirsova, Davide Povero, Samar H. Ibrahim
View: Text | PDF
Research Article Hepatology Vascular biology

Endothelial cell glycogen synthase kinase 3β promotes lipotoxic endotheliopathy and liver inflammation in MASH

  • Text
  • PDF
Abstract

In metabolic dysfunction–associated steatohepatitis (MASH), liver sinusoidal endothelial cells (LSECs) acquire a proinflammatory phenotype termed lipotoxic endotheliopathy. We previously identified glycogen synthase kinase 3β (GSK3β) as a central signaling hub in LSECs during MASH. To elucidate the molecular mechanisms and functional outcome of lipotoxicity-induced GSK3β activation in LSECs, we utilized endothelial cell–specific Gsk3β-KO (Gsk3βΔEnd) mice fed MASH-inducing diets. Endothelial Gsk3β deletion significantly reduced markers of lipotoxic endotheliopathy, including adhesion molecules and chemokines, alongside liver injury, inflammation, and fibrosis. Immune profiling via flow cytometry and mass cytometry by time of flight (CyTOF) identified decreased hepatic infiltration of proinflammatory myeloid populations, particularly mature DCs in Gsk3βΔEnd mice. In a coculture system, GSK3β in lipotoxic LSECs promoted DCs maturation. Mechanistically, GSK3 inhibition restored lipotoxicity-induced alterations in LSEC mitochondrial morphology and respiration by regulating AMP-activated protein kinase and dynamin-related protein 1. This rescue suppressed chemokine and adhesion molecule expression, thereby limiting immune cell recruitment. Collectively, under lipotoxic stress, GSK3β amplifies mitochondrial dysfunction and inflammatory signaling in LSECs, enhancing myeloid cell homing and DC maturation. Targeting LSEC GSK3β may, therefore, represent a promising therapeutic strategy to mitigate LSEC-driven fibroinflammatory response in human MASH.

Authors

Akitoshi Sano, Qianqian Guo, Khaled Warasnhe, Chady Meroueh, Nantawat Satthawiwat, Asma Hamdi, Ghefar Hmaydoosh, Xin Dai, Usman Yaqoob, Kevin D. Pavelko, Charlene Miciano, Tatiana Kisseleva, Zeba Firdaus, Patrick P. Starlinger, David Pereyra, Enis Kostallari, Petra Hirsova, Davide Povero, Samar H. Ibrahim

×

Figure 7

LSEC mitochondrial dysfunction drives inflammation in lipotoxicity and MASH via NF-κB and MYC activation.

Options: View larger image (or click on image) Download as PowerPoint
LSEC mitochondrial dysfunction drives inflammation in lipotoxicity and M...
(A) mRNA expression of Il1b, Il6, and Ccl2 in LSECs isolated from mice. (B) mRNA expression of IL1B, IL6, and CCL2 in hLSECs treated with palmitate and GSK3 inhibitor LY. (C) mRNA expression of Nfkbia and Tnfaip3 in primary mouse LSECs treated with 500 μM palmitate for 2 hours. (D) mRNA expression of NFKBIA and TNFAIP3 in hLSECs treated with 800 μM palmitate and the GSK3 inhibitor LY for 2 hours. (E and F) Representative images of primary mouse LSECs (E) and hLSECs (F) treated with palmitate, Mdivi1, and antimycin A, stained with MitoTracker (green) and MitoSOX (red). Scale bar: 5 μm. The MitoSOX quantification is shown in the right panel. (G) mRNA expression of NFKBIA and TNFAIP3 in hLSECs treated with 800 μM palmitate, Mdivi1, and antimycin A for 2 hours. (H) mRNA expression of ICAM1, CXCL1, CXCL2, and CXCL10 in hLSECs treated with palmitate and Mdivi1. (I) mRNA expression of MYC in hLSECs treated with palmitate, GSK3 inhibitor LY and Mdivi. (J) mRNA expression of MYC, ICAM1, CXCL1, CXCL2, and CXCL10 in hLSECs following MYC silencing by siRNA. Bar graphs represent the mean ± SEM; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (1-way ANOVA with Bonferroni’s multiple comparison).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts